

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES...

CONCORD BIOTECH Biotech for Mankind... CONCORD BIOTECH LIMITED



Please scan this QR code to view the Red Herring Prospectus and the abridged prospectus.

Our Company was originally incorporated as 'Sermovmed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 23, 1984...

PROMOTERS OF OUR COMPANY: SUDBIR VAID AND ANKUR VAID

INITIAL PUBLIC OFFER OF UP TO 20,925,652 EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH ("EQUITY SHARES") OF CONCORD BIOTECH LIMITED ("COMPANY") FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹ [•] PER EQUITY SHARE) ("OFFER PRICE")...

Table with 3 columns: NAME OF THE SELLING SHAREHOLDER, NUMBER OF EQUITY SHARES OFFERED, WEIGHTED AVERAGE COST OF ACQUISITION.

Concord Biotech Limited is an India-based biopharma company and global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology.

QIB Portion: Not more than 50% of the Net Offer | Non-Institutional Portion: Not less than 15% of the Net Offer | Retail Portion: Not less than 35% of the Net Offer | Employee Reservation Portion: Up to 10,000 Equity Shares aggregating up to ₹ [•] million

PRICE BAND: ₹ 705 TO ₹ 741 PER EQUITY SHARE OF FACE VALUE OF ₹ 1 EACH | THE FLOOR PRICE IS 705 TIMES AND THE CAP PRICE IS 741 TIMES THE FACE VALUE OF THE EQUITY SHARES RESPECTIVELY

In accordance with the recommendation of a Committee of Independent Directors of the Company, pursuant to their resolution dated July 28, 2023, the above provided price band is justified based on the KPIs, disclosed in the "Basis of Offer Price" section of the RHP beginning on page 92.

Risks to Investors:

- 1. Market Risk: The Offer Price of our Equity Shares, our market capitalization to revenue from operations for FY 2023 and our market capitalization to total income for FY 2023, our price-to-earnings (P/E) ratio and our enterprise value to EBITDA ratio may not be indicative of the market price of our Equity Shares after the Offer.

Table with 6 columns: Particulars, 2021 Amount, 2021 %, 2022 Amount, 2022 %, 2023 Amount, 2023 %.

Table with 6 columns: Particulars, 2021 (₹ in millions), 2021 %, 2022 (₹ in millions), 2022 %, 2023 (₹ in millions), 2023 %.

Table with 6 columns: Particulars, 2021 (₹ in millions), 2021 %, 2022 (₹ in millions), 2022 %, 2023 (₹ in millions), 2023 %.

- 4. Customer concentration risk: We derive, and may continue to derive, a significant portion of our revenue from a limited number of customers.

- 5. Concentration Risk: We have three manufacturing facilities and two dedicated research and development ("R&D") units, which are all located in Gujarat, India.

Table with 7 columns: Date of allotment, No. of Equity Shares allotted, Face value per Equity Share, Issue price per Equity Share, Nature of allotment, Nature of consideration, Total consideration.

- 9. The three Book Running Lead Managers associated with the Offer have handled 33 public issues in the past three Financial Years, out of which 10 issues closed below the issue price on the listing date:

Table with 3 columns: Name of the BRLMs, Total Public Issues, Issues closed below IPO price on listing date.

BID/OFFER PROGRAMME BID/OFFER OPENS TODAY BID/OFFER CLOSES ON TUESDAY, AUGUST 8, 2023*

*UPI mandate end time and date shall be 5.00 p.m. on the Bid/Offer Closing Date.

ASBA* Simple, Safe, Smart way of Application!!! UPI-Now available in ASBA for UPI Bidders applying through Registered Brokers, DPs and RTAs.

*Applications Supported by Blocked Amount ("ASBA") is a better way of applying to offers by simply blocking the fund in the bank account. For further details, check section on ASBA. Mandatory in public issues. No cheque will be accepted.

BOOK RUNNING LEAD MANAGERS: Kotak Investment Banking, Citi, Jefferies. REGISTER TO THE OFFER: Link Intime. COMPANY SECRETARY AND COMPLIANCE OFFICER: Prakash Sajani.

In case of any revision to the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days following such revision of the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days.

Place: Ahmedabad Date: Thursday, August 3, 2023

CONCORD BIOTECH LIMITED is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed a draft red herring prospectus dated August 12, 2022 (the "DRHP") with SEBI and has filed the red herring prospectus dated July 27, 2023 with the RoC (the "RHP").